A genetics-led approach defines the drug target landscape of 30 immune-related traits
Most candidate drugs currently fail later-stage clinical trials, largely due to poor prediction of efficacy on early target selection1. Drug targets with genetic support are more likely to be therapeutically valid2,3, but the translational use of genome-scale data such as from genome-wide associat...
主要な著者: | Fang, H, De Wolf, H, Knezevic, B, Burnham, K, Osgood, J, Sanniti, A, Lledó Lara, A, Kasela, S, De Cesco, S, Wegner, J, Handunnetthi, L, McCann, F, Chen, L, Sekine, T, Brennan, P, Marsden, B, Damerell, D, O’Callaghan, C, Bountra, C, Bowness, P, Sundström, Y, Milani, L, Berg, L, Göhlmann, H, Peeters, P, Fairfax, B, Sundström, M, Knight, J |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
Springer Nature
2019
|
類似資料
-
Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease
著者:: Handunnetthi, L, 等
出版事項: (2021) -
High-throughput structural characterisation of therapeutic protein targets.
著者:: Marsden, B, 等
出版事項: (2006) -
High-throughput structural characterisation of therapeutic protein targets
著者:: Marsden, B, 等
出版事項: (2006) -
Insights for the development of specific kinase inhibitors by targeted structural genomics.
著者:: Fedorov, O, 等
出版事項: (2007) -
Science Forum: Donated chemical probes for open science
著者:: Müller, S, 等
出版事項: (2018)